Harrow Inc
HROW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.58B
Close$
$13.51
67.3% downside
Current Fair Value
67.3% downsideOvervalued by 67.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.58 Billion |
|---|---|
| Enterprise Value | $1.79 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.26 |
| Outstanding Shares | 37,231,321 |
Return
| Return on Equity | -52.12% |
|---|---|
| Return on Assets | -3.57% |
| Return on Invested Capital | -0.23% |
Valuation & Multiples
| P/E Ratio | -108.23 |
|---|---|
| PEG | -195.92 |
| Price to Sales | 5.91 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.66 |
| Enterprise Value to EBIT | -2342.24 |
| Enterprise Value to Net Income | -120 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 10.47 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
$52.55 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$70.62 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 50.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 58.20% |
|---|---|
| Total Invested | $659,518▼ 99.91% |
| Investors Holding | 9▼ 217.00% |
ESG Score
No data
About Harrow Health Inc
125 employeesHarrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...